patient
chronic
obstruct
pulmonari
diseas
copd
prone
frequent
exacerb
major
caus
morbid
mortal
reduct
effect
treatment
exacerb
may
signific
previou
studi
shown
patient
sever
sever
air
flow
limit
tend
high
risk
exacerb
higher
exacerb
rate
associ
faster
loss
forc
expiratori
volum
second
greater
worsen
overal
health
exacerb
copd
caus
bacteri
infect
studi
convent
method
establish
approxim
exacerb
caus
bacteri
infect
nevertheless
convent
diagnost
method
often
insuffici
etiolog
diagnosi
half
case
pathogen
use
multiplex
polymeras
chain
reaction
pcr
reliabl
molecular
method
diagnos
lower
respiratori
tract
infect
increas
recent
year
promin
advantag
pcr
method
compar
cultur
sinc
pcr
method
base
replic
deoxyribonucl
acid
dna
ribonucl
acid
rna
small
amount
microorgan
requir
live
organ
therefor
affect
use
antibiot
addit
pcr
sensit
detect
multipl
microorgan
deliv
fast
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
common
bacteri
pathogen
involv
pose
sever
question
possibl
increas
frequenc
exacerb
patient
sever
air
flow
limit
relat
increas
infecti
origin
exacerb
may
isol
bacteri
agent
relat
clinic
characterist
besid
previous
global
initi
chronic
obstruct
lung
diseas
gold
public
defin
grade
stage
expiratori
air
flow
obstruct
reliabl
predict
degre
breathless
exercis
limit
exacerb
health
statu
impair
patient
copd
gold
report
ad
symptom
includ
copd
assess
test
cat
modifi
british
medic
research
council
mmrc
exacerb
risk
help
defin
risk
group
sever
stage
studi
base
previou
gold
stage
system
signific
relationship
low
frequenc
variou
organ
includ
pseudomona
aeruginosa
enterobacteriacea
howev
similar
studi
includ
symptom
score
exacerb
frequenc
group
classifi
accord
new
gold
stage
system
studi
design
analyz
relationship
isol
frequenc
varieti
potenti
pathogen
bacteria
ppb
new
gold
stage
acut
exacerb
copd
aecopd
ppb
obtain
convent
sputum
cultur
pcr
method
addit
studi
one
studi
compar
highli
sensit
pcr
method
cultur
method
aecopd
consecut
patient
aecopd
appli
konya
numun
hospit
pulmonolog
depart
konya
turkey
septemb
decemb
ambulatori
undergo
inpati
treatment
includ
studi
patient
diagnos
copd
accord
gold
criteria
exist
three
criteria
describ
previous
dyspnea
sputum
volum
increas
sputum
purul
search
diagnosi
acut
patient
histori
antibiot
use
last
day
accompani
bronchiectasi
verifi
highresolut
comput
tomographi
pneumonia
immunosuppress
malign
congest
heart
failur
includ
studi
cat
pulmonari
function
test
accord
american
thorac
societi
provid
patient
pulmonari
function
test
perform
technician
administr
salbutamol
patient
stabl
exacerb
histori
note
combin
copd
assess
scale
appli
accord
gold
criteria
patient
divid
four
group
gold
b
c
sputum
sampl
taken
patient
steril
contain
rins
mouth
throat
analyz
microscop
gram
stain
without
wait
sputum
sampl
observ
fewer
ten
epitheli
cell
leukocyt
area
upon
magnif
includ
studi
appropri
sputum
sampl
patient
inform
studi
written
consent
taken
consent
univers
meram
medic
faculti
ethic
committe
taken
studi
gram
stain
direct
microscop
examin
sputum
sampl
incub
hour
inocul
eosin
methylen
blue
agar
blood
agar
brucella
agar
chocol
agar
media
result
analyz
clinic
sampl
genom
dna
isol
pcr
step
revers
line
blot
hybrid
assay
studi
multiplex
pcr
method
capbacpn
mix
gen
autoimmun
diagnostika
gmbh
germani
kit
studi
detect
pneumonia
h
influenza
catarrhali
chlamydophila
pneumonia
mycoplasma
pneumonia
legionella
pneumophila
staphylococcu
aureu
klebsiella
pneumonia
escherichia
coli
enterobact
cloaca
bacteria
done
rdb
bac
hospit
gen
autoimmun
diagnostika
gmbh
multiplex
pcr
kit
accord
expert
suggest
spss
version
ibm
corpor
armonk
ny
usa
program
use
statist
analysi
independentsampl
ttest
comparison
parametr
data
among
group
u
test
comparison
nonparametr
data
test
multipl
nonparametr
group
comparison
use
limit
statist
signific
accept
p
least
one
bacteri
growth
detect
patient
cultur
commonli
grown
bacteria
base
cultur
studi
pneumonia
h
influenza
tabl
bacteria
reproduc
group
elev
term
quantiti
divers
p
aeruginosa
e
coli
acinetobact
baumannii
reproduc
group
patient
tabl
howev
signific
differ
gold
stage
cultur
result
patient
differ
age
cat
score
exacerb
frequenc
isol
cultur
tabl
realtim
pcr
studi
similar
ratio
direct
microscopi
least
one
bacteri
agent
obtain
patient
tabl
pcr
signific
differ
ppb
isol
exacerb
frequenc
signific
relationship
gold
stage
cat
score
age
pcr
result
tabl
cultur
quantiti
divers
bacteria
group
higher
moreov
mix
infecti
agent
frequenc
observ
elev
group
distribut
bacteria
accord
stage
shown
tabl
compar
pcr
cultur
method
term
bacteri
detect
rate
detect
rate
pcr
significantli
higher
bacteri
growth
detect
cultur
patient
pcr
method
abl
detect
bacteria
patient
pcr
method
detect
bacteria
patient
posit
cultur
two
patient
posit
cultur
bacteria
accord
pcr
result
signific
differ
cultur
pcr
method
term
detect
rate
multipl
pathogen
p
pcr
method
abl
detect
multipl
bacteria
case
cultur
method
detect
multipl
pathogen
test
case
studi
design
investig
relationship
ppb
isol
frequenc
gold
stage
aecopd
howev
relationship
stage
bacteria
isol
found
similarli
correl
cat
score
ppb
frequenc
found
signific
relationship
ppb
isol
exacerb
frequenc
acut
exacerb
advers
affect
prognosi
diseas
acceler
process
result
sever
respiratori
failur
result
consider
load
health
care
expenditur
countri
signific
amount
labor
forc
loss
howev
controversi
antibiot
treatment
need
exacerb
amount
sputum
evalu
increas
purul
seem
best
method
indic
start
antibiot
determin
factor
convent
sputum
cultur
method
difficult
time
consum
reason
clinician
initi
empir
antibiot
treatment
without
wait
cultur
know
frequenc
resist
characterist
microbiolog
organ
exacerb
societi
necessari
ration
antibiot
select
treatment
success
initi
empir
antibiot
treatment
mani
nation
region
studi
agent
cultur
serolog
method
conduct
studi
form
foundat
empir
treatment
studi
pcr
studi
similar
previou
studi
pneumonia
h
influenza
common
bacteria
sputum
cultur
p
aeruginosa
e
coli
baumannii
isol
gold
stage
patient
howev
signific
differ
gold
stage
cultur
result
patient
mani
studi
copd
acut
exacerb
pneumonia
h
influenza
catarrhali
found
predomin
bacteri
organ
degre
function
respiratori
impair
copd
patient
also
associ
presenc
differ
bacteria
sputum
sampl
cours
shown
isol
ratio
p
aeruginosa
enterobacteriacea
gramneg
bacteria
coincid
common
factor
patient
sever
sever
studi
li
et
aureu
p
aeruginosa
e
coli
baumannii
isol
patient
valu
howev
pneumonia
found
occur
frequent
mild
moder
copd
h
influenza
found
approxim
equal
three
group
studi
eller
et
correl
impair
lung
function
bacteria
isol
obtain
frequenc
gramneg
organ
includ
pseudomona
klebsiella
enterobacteriacea
higher
sever
sever
well
known
convent
cultur
test
low
sensit
specif
detect
microorgan
select
environ
cultur
prevent
growth
presenc
one
type
organ
disadvantag
consequ
use
differ
media
differ
organ
need
least
day
result
molecular
techniqu
develop
recent
maintain
fast
reliabl
identif
respiratori
dna
rna
small
amount
microorgan
isol
pcr
method
contrast
cultur
pcr
depend
viabl
bacteria
valuabl
tool
patient
need
antibiot
et
found
pneumonia
isol
rate
increas
h
influenza
isol
rate
increas
binari
detect
rate
microorgan
increas
studi
compar
bronchoalveolar
lavag
fluid
cultur
pcr
present
studi
pcr
discriminatori
cultur
posit
sampl
vs
patient
posit
cultur
microorgan
detect
pcr
two
sampl
pcr
neg
situat
explain
presenc
factor
may
inhibit
pcr
sampl
ie
blood
tissu
milk
plant
moreov
mix
infect
found
cultur
detect
pcr
mix
infect
frequenc
higher
gold
stage
patient
signific
differ
gold
stage
cat
score
pcr
result
studi
reveal
relat
exacerb
frequenc
bacteri
isol
patient
present
frequent
exacerb
greater
bacteri
isol
suggest
greater
degre
colon
fact
mani
year
exist
bacteri
colon
airway
known
patient
stabl
compar
studi
healthi
control
group
colon
h
influenza
pneumonia
catarrhali
p
aeruginosa
aureu
protect
specimen
sampl
patient
stabl
copd
present
although
impact
colon
bacteria
acut
exacerb
yet
clear
recent
present
increas
bacteri
load
exacerb
prolifer
new
strain
relationship
acut
studi
evalu
paramet
associ
bacteri
colon
consid
patel
et
observ
patient
copd
day
found
signific
relationship
exacerb
frequenc
increas
colon
find
relationship
airway
obstruct
colon
similarli
zhang
et
studi
base
observ
patient
copd
year
present
posit
correl
lower
airway
bacteri
colon
exacerb
frequenc
could
find
relationship
colon
therefor
lower
airway
bacteri
colon
seem
frequent
patient
frequent
exacerb
howev
whether
colon
caus
frequent
exacerb
vice
versa
studi
ppb
isol
frequent
patient
frequent
exacerb
studi
design
discrimin
colon
activ
infect
exacerb
confirm
patient
clinic
isol
ppb
consid
caus
infect
even
isol
ppb
reflect
colon
still
use
indic
infecti
agent
previou
patient
present
colon
develop
infect
result
new
strain
fact
sethi
et
studi
period
month
sputum
sampl
cultur
collect
monthli
exacerb
outpati
copd
ppb
isol
stabl
period
versu
exacerb
period
illustr
caus
acut
exacerb
new
strain
pathogen
present
studi
relationship
exacerb
frequenc
bacteria
isol
found
henc
term
bacteri
etiolog
exacerb
frequenc
seem
better
indic
compar
gold
stage
viral
factor
respons
approxim
commonli
rhinovirus
follow
metapneumoviru
influenza
b
parainfluenza
coronaviru
adenoviru
respiratori
syncyti
viru
isol
patient
also
signific
proport
patient
bacteri
viral
agent
isol
mix
infect
frequent
patient
sever
copd
unfortun
cost
studi
identifi
concurr
viral
pathogen
situat
one
limit
studi
anoth
limit
studi
small
number
sampl
due
high
cost
studi
show
bacteri
infect
copd
may
independ
caus
acut
exacerb
stage
may
two
reason
explain
differ
group
frequent
exacerb
symptom
lower
valu
term
bacteri
isol
frequenc
compar
group
patient
classifi
accord
new
gold
stage
first
sever
patient
lung
function
alreadi
lower
limit
probabl
sensit
noninfecti
agent
air
pollut
heart
failur
show
acut
exacerb
symptom
quickli
air
pollut
environment
condit
increas
airway
inflamm
bronchomotor
tone
may
account
high
air
pollut
rate
region
studi
conduct
also
support
thesi
way
condit
may
synchron
mild
period
copd
patient
affect
easili
noninfecti
caus
second
averag
studi
high
predict
averag
group
patient
may
differ
result
sever
copd
patient
lower
valu
knowledg
present
studi
first
compar
new
gold
stage
system
ppb
isol
rate
conclus
isol
ppb
varieti
mix
infect
frequenc
found
higher
gold
group
patient
result
indic
necess
cautiou
select
empir
antibiot
patient
propos
necess
prospect
studi
base
longterm
monitor
contain
group
lower
score
conduct
wide
patient
popul
